Skip to main content

Other current therapy areas

Paediatric endocrinology

Interested in paediatric endocrinology?

Visit our dedicated microsite for research news, interviews and in-depth analysis of paediatric endocrinology and growth disorders.

  • Higher vitamin D supplementation doses needed for effectiveness in children

  • Young age among predictors of weight gain after paediatric Graves’ disease treatment

Pulmonary hypertension

06-03-2017 | Pulmonary hypertension | News | Article

Systemic sclerosis associated with poor survival in CTD-PAH

A Chinese cohort study identifies factors associated with prognosis among patients with connective tissue disease-associated pulmonary arterial hypertension.

03-03-2017 | Pulmonary hypertension | News | Article

Right atrial strain associated with clinical outcomes in PAH

Study results suggest that right atrial strain could predict adverse outcomes among patients with pulmonary arterial hypertension.

10-02-2017 | Pulmonary hypertension | News | Article

Post-treatment pulmonary arterial compliance best predicts PAH prognosis

Evaluation of pulmonary arterial compliance after initiation or escalation of therapy for pulmonary arterial hypertension more accurately predicts prognosis than conventional right heart hemodynamic parameters, Italian study findings indicate.


29-09-2017 | HBV | News | Article

Novel indices to diagnose fibrosis in chronic HBV patients developed

Two research groups have developed noninvasive indices to detect significant fibrosis in treatment-naïve patients with chronic hepatitis B virus infection, one using serum levels of Golgi protein 73 and liver stiffness, and the other based on the ratio of gamma-glutamyl transpeptidase to albumin.

26-09-2017 | HBV | News | Article

Sex modifies age-related HCC risk after HBsAg clearance

Achieving hepatitis B surface antigen seroclearance neutralizes the increased risk for hepatitis B virus-related hepatocellular carcinoma among women aged 50 years or younger, but not among older women or men regardless of their age, research indicates.

26-09-2017 | HBV | News | Article

Treatment-induced liver stiffness reduction lowers HCC risk in HBV patients

Achieving a subcirrhotic liver stiffness level after antiviral therapy halves the risk for hepatocellular carcinoma in patients with chronic hepatitis B virus-related advanced fibrosis or cirrhosis, Korean research shows.


04-10-2017 | Asthma | News | Article

B cells have key role in Th-mediated allergic response

Results of a study conducted in mouse models of allergy suggest that B cells have an important role in propagating T-helper cell-mediated responses to house dust mites.

04-10-2017 | Asthma | News | Article

Blood eosinophils vary over time in relation to exacerbation and asthma control

Analysis of the COBRA cohort of adult patients with asthma provides insights into the role eosinophil count plays as a biomarker for predicting exacerbations and treatment efficacy.

04-09-2017 | Asthma | News | Article

Japanese subphenotypes of type 2 severe asthma identified

The majority of Japanese patients with severe, difficult-to-treat asthma are likely to present with type 2 asthma and a substantial proportion overlap between two or more subphenotypes, a study suggests.


17-11-2017 | Rheumatology | News | Article

Online self-management program boosts JIA HRQoL

An internet-based educational tool developed by Canadian researchers helps adolescents with juvenile idiopathic arthritis to manage their disease and leads to improvements in their health-related quality of life relative to standard disease education.

16-11-2017 | Rheumatology | News | Article

Exploring RA treatment patterns

Several studies presented at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA, explored different aspects of rheumatoid arthritis treatment, including guideline recommendations, adherence to second-line therapy, and predicting treatment response.

15-11-2017 | Rheumatology | News | Article

Extended benefits of ixekizumab treatment in patients with PsA

Results from the extension phase of the SPIRIT-P2 trial suggest that the benefits of treatment with ixekizumab are maintained for up to 1 year among patients with psoriatic arthritis.

image credits